![Bernd Hentsch](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernd Hentsch
Director/Miembro de la Junta en G2M Cancer Drugs AG .
Origen de la red de primer grado Bernd Hentsch.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
G2M Cancer Drugs AG
![]() G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Bernd Hentsch a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
![]() igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Biotechnology | Chief Executive Officer | |
Cardion GmbH
![]() Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Medical Specialties | Chief Executive Officer | |
Satosea Oncology GmbH | Chief Executive Officer | ||
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | Pharmaceuticals: Major | Chairman | |
Technische Universität Braunschweig | College/University | Corporate Officer/Principal | |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Eberhard Karls Universität Tübingen | College/University | Undergraduate Degree | |
Minaris Regenerative Medicine GmbH
![]() Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Biotechnology | Chairman | |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Igeneon AG | Chief Executive Officer | ||
Max Planck Institute For Biophysical Chemistry | College/University | Doctorate Degree | |
Aphton Corp.
![]() Aphton Corp. BiotechnologyHealth Technology Aphton Corp. operates as a biopharmaceutical company, which is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and gastrointestinal disease. The company was founded on May 12, 1981 and is headquartered in Philadelphia, PA. | Biotechnology | Chief Operating Officer | |
Kiadis Pharma Deutschland GmbH
![]() Kiadis Pharma Deutschland GmbH Pharmaceuticals: MajorHealth Technology Kiadis Pharma Deutschland GmbH develops drugs for blood cancer. The private company is based in Munich, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Kiadis Pharma Canada, Inc.
![]() Kiadis Pharma Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kiadis Pharma Canada, Inc. manufactures and supplies pharmaceutical products. The company is based in Saint-Laurent, Canada. | Pharmaceuticals: Major | Chief Executive Officer | |
Affectis Pharmaceuticals AG
![]() Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
LSP Services Deutschland GmbH | Investment Managers | Private Equity Investor | |
4SC AG | Biotechnology | Director/Board Member | |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Chief Executive Officer |
Estadísticas
Internacional
Alemania | 15 |
Austria | 4 |
Países Bajos | 3 |
Estados Unidos | 2 |
Canadá | 2 |
Sectorial
Health Technology | 13 |
Consumer Services | 4 |
Commercial Services | 3 |
Finance | 2 |
Health Services | 2 |
Operativa
Chief Executive Officer | 12 |
Director/Board Member | 3 |
Chairman | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Las relaciones más conectadas
Insiders | |
---|---|
Manfred Rüdiger | 22 |
- Bolsa de valores
- Insiders
- Bernd Hentsch
- Conexiones Empresas